Home Blog of Signal Transduction Cell Cycle Wee1

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Wee1

Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review

63 views | Jan 24 2024

This systematic review consolidates evidence showcasing the promising efficacy of WEE1 inhibitors in gynecological malignancies while highlighting the significance of biomarker-driven patient selection for optimizing treatment response. [Read the Full Post]

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

127 views | Oct 09 2022

Pia Roering et al. found that Wee1 inhibitor adavosertib affected several critical functions related to proliferation, cell cycle and division, apoptosis, and invasion. [Read the Full Post]

Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study

91 views | Jul 14 2022

Sabine Mueller et al. found that adavosertib in combination with CRT was well tolerated in children with newly diagnosed DIPG, however, compared to historical controls, did not improve OS. [Read the Full Post]

Evidence of Rate Limiting Proton Transfer in an S N Ar Aminolysis in Acetonitrile under Synthetically Relevant Conditions

253 views | Nov 15 2021

Ian W Ashworth et al. found that 1-methylpiperazine, and the piperazine derived impurity correlated in a Brønsted type analysis with the pKa's (acetonitrile) of the amine nucleophile. [Read the Full Post]

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores

279 views | Aug 20 2021

K E Broekman et al. found that only a few licensed systemic therapies for recurrent ovarian cancer showed substantial clinical benefit based on ESMO-MCBS scores. [Read the Full Post]

Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines

262 views | Nov 27 2020

Carmelina Antonella Iannuzzi et al. suggested that the dl922-947-AZD1775 combination could be a feasible strategy against MM. [Read the Full Post]

The Apparent Requirement for Protein Synthesis during G2 Phase Is due to Checkpoint Activation

338 views | Jul 29 2020

Sarah Lockhead et al. showed that protein synthesis during G2 phase was not required for mitotic entry, at least when the p38 checkpoint pathway was abrogated. [Read the Full Post]

Orthotopic patient-derived xenografts of paediatric solid tumours

394 views | Apr 06 2020

Stewart E et al. identified several drug vulnerabilities and showed that the combination of a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts tumours in vivo. [Read the Full Post]

WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance

398 views | Mar 14 2020

Zheng H et al. demonstrated that combined cisplatin treatment and WEE1 inhibition synergistically inhibits xenograft cancer growth accompanied by markedly reduced expression of TNBC signature genes. [Read the Full Post]

Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis

0 views | Oct 10 2019

Chen G et al. provided a novel therapeutic strategy to optimize MK-1775 treatment efficiency in lung cancers. [Read the Full Post]